|
Video: What is a Stock Split?
|
|
Trinity Biotech develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Co. is also a provider of raw materials to the life sciences and research industries globally. Co. markets its portfolio of products to customers through its own sales force and a network of international distributors and partners. The brand names of the products of Co. include UniGold, Recombigen, MarDx, FlexTrans, Premier, Ultr, ImmuBlot, ImmuGlo, ImmuLisa, OTOblot, EZ, and Captia. According to our TRIB split history records, Trinity Biotech has had 1 split. | |
|
Trinity Biotech (TRIB) has 1 split in our TRIB split history database. The split for TRIB took place on February 23, 2024. This was a 1 for 5 reverse split, meaning for each 5 shares of TRIB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.
When a company such as Trinity Biotech conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TRIB split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Trinity Biotech shares, starting with a $10,000 purchase of TRIB, presented on a split-history-adjusted basis factoring in the complete TRIB split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
04/30/2014 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$122.55 |
|
End price/share: |
$1.83 |
|
Starting shares: |
81.60 |
|
Ending shares: |
83.37 |
|
Dividends reinvested/share: |
$2.20 |
|
Total return: |
-98.47% |
|
Average Annual Total Return: |
-34.19% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$152.55 |
|
Years: |
10.00 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/30/2014 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$122.55 |
|
End price/share: |
$1.83 |
|
Dividends collected/share: |
$2.20 |
|
Total return: |
-96.71% |
|
Average Annual Total Return: |
-28.93% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$329.06 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
02/23/2024 | 1 for 5 |
|
|